Castle Biosciences Inc.

21.01
0.49 (2.39%)
At close: Mar 24, 2025, 3:59 PM
20.86
-0.73%
After-hours: Mar 24, 2025, 06:02 PM EDT
2.39%
Bid 20.19
Market Cap 599.08M
Revenue (ttm) 336.65M
Net Income (ttm) 18.5M
EPS (ttm) 0.62
PE Ratio (ttm) 33.89
Forward PE -16.79
Analyst Strong Buy
Ask 21.52
Volume 104,486
Avg. Volume (20D) 482,822.5
Open 20.83
Previous Close 20.52
Day's Range 20.65 - 21.14
52-Week Range 16.96 - 35.84
Beta 0.98

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients w...

Sector Healthcare
IPO Date Jul 25, 2019
Employees 761
Stock Exchange NASDAQ
Ticker Symbol CSTL
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $40, which is an increase of 90.39% from the latest price.

Stock Forecasts

Next Earnings Release

Castle Biosciences Inc. is scheduled to release its earnings on May 1, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-14.24%
Castle Biosciences shares are trading lower. The c... Unlock content with Pro Subscription
2 months ago
-13.55%
Castle Biosciences shares are trading lower after the company reported preliminary FY24 financial results.